Personalis Adds Resistance Mutation Tracking to NeXT Personal Cancer Test

Key Points

• Personalis commercially launched Real-Time Variant Tracker as an optional addition to its NeXT Personal molecular residual disease test report.
• The supplemental results track clinically relevant genetic changes, including mutations associated with treatment resistance and potential treatment targets.
• Included variants have established clinical significance, such as links to FDA-approved therapies or recommendations in NCCN guidelines.
• The feature became commercially available October 20, following an early access program launched in January 2026.

Personalis (NASDAQ: PSNL) has expanded its NeXT Personal cancer monitoring test with an optional feature designed to track how cancer’s genetic makeup changes over time.

Called Real-Time Variant Tracker, the supplemental results add information about resistance mutations and potentially targetable variants during ongoing NeXT Personal testing.

New Feature Tracks Changes That May Be Relevant to Treatment

NeXT Personal testing monitors very low levels of circulating tumor DNA, or ctDNA. The new supplemental results are intended to help clinicians follow genetic changes that may emerge during that monitoring.

Rather than focusing only on whether cancer-related DNA is detected, the feature adds information about variants that could be relevant to treatment resistance or therapy selection.

Personalis says the tracker includes variants with established clinical significance, including associations with FDA-approved treatments and recommendations in National Comprehensive Cancer Network guidelines. That does not mean every detected variant will identify an appropriate treatment for an individual patient.

Commercial Launch Follows January Early Access Program

Personalis introduced the feature to select clinical and academic users through an early access program in January 2026.

As of October 20, it is commercially available as an optional supplemental result within the NeXT Personal report—not as a separate standalone test.

Investor Takeaway: Broader Test Capabilities, With Financial Impact Undisclosed

For PSNL investors, the launch expands the information available through an existing testing platform and could make its reports more useful for clinicians following cancer over time.

The announcement does not disclose pricing, expected adoption, additional revenue or new evidence that the feature improves patient outcomes. Those remain important measures of its clinical and commercial impact.